Study: Precision Medicine Yields Better Outcomes in Phase I Clinical Trials

Parexel releases report on advancing precision oncology

Parexel, one of the world’s largest clinical research organizations providing the full range of phase I to IV clinical development services, has released a new report in their expert series, New Medicines, Novel Insights.

May 24, 2024

Vol.50 No.21

Clinical Trials & Tribulations

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.

May 10, 2024

Vol.50 No.19

By Sanju Sinha and Eytan Ruppin

In Brief

Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

The Northwell Health Cancer Institute and its Center for Genomic Medicine opened Long Island’s first clinical Molecular Diagnostics Laboratory, a $3.2 million 2,800 square foot state-of-the-art facility with technology of next-generation sequencing that provides point-of-care tumor and patient genomic profiling to inform precision cancer therapy.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Drugs & Targets

Tempus contributes de-identified cancer data to NCI’s planned data enclave

Tempus has sent de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the NCI.

March 22, 2024

Vol.50 No.12

Real-world Evidence

Flatiron, Caris combine EHR, multi-omics data to support precision oncology

Two major cancer informatics companies—Flatiron Health and Caris Life Sciences—have created a partnership to generate combined biological and clinical real-world evidence datasets that can be used to inform the development of immuno-oncology agents and targeted cancer therapeutics.

January 26, 2024

Vol.50 No.04

By Matthew Bin Han Ong